﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>BioSpectrum Asia - RSS Feed</title>
    <link>http://biospectrumasia.ciol.com/rss/</link>
    <description>BioSpectrum Asia is a specialized information platform for life science articles in the Asia Pacific that includes life sciences articles, pharma news, life science products reviews and other information</description>
    <language>en-us</language>
    <pubDate>9/2/2010 5:30:04 PM</pubDate>
    <lastBuildDate>9/2/2010 5:30:04 PM</lastBuildDate>
    <docs>http://biospectrumasia.ciol.com/rss/</docs>
    <generator>BSA Feed Generator</generator>
    <managingEditor>sureshn@cybermedia.co.in</managingEditor>
    <webMaster>webmasterciol@cybermedia.co.in</webMaster>
    <item>
      <title>Agensys initiates phase I of renal cancer drug</title>
      <link>http://www.biospectrumasia.com/content/020910JPN13758.asp</link>
      <description>Astellas'' affiliate has started trials of AGS-16M8F an antibody-drug conjugate for treating metastatic renal cancer</description>
      <pubDate>9/2/2010 5:01:48 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910JPN13758.asp</guid>
    </item>
    <item>
      <title>Scientists discover protein that fuels Alzheimer''s disease</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13757.asp</link>
      <description>Researchers at the Fisher Center for Alzheimer''s Disease Research have discovered a protein that stimulates the production of beta-amyloid, representing a major new advance in Alzheimer''s disease research.</description>
      <pubDate>9/2/2010 4:41:37 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13757.asp</guid>
    </item>
    <item>
      <title>Pfizer to acquire drug developer FoldRx</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13756.asp</link>
      <description>US-based pharma giant Pfizer agreed to acquire privately held drug discovery and clinical development company FoldRx Pharmaceuticals</description>
      <pubDate>9/2/2010 4:34:32 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13756.asp</guid>
    </item>
    <item>
      <title>Varian establishes radiotherapy training center in India</title>
      <link>http://www.biospectrumasia.com/content/020910IND13755.asp</link>
      <description>Varian Medical, a manufacturer of medical devices for treating cancer with radiotherapy, has established its first education center in India to train medical physicists and technologists working on the company''s cancer treatment systems.</description>
      <pubDate>9/2/2010 3:01:36 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910IND13755.asp</guid>
    </item>
    <item>
      <title>Yongye enters into $59 mn revolving credit facilities</title>
      <link>http://www.biospectrumasia.com/content/020910CHN13754.asp</link>
      <description>Yongye International, a manufacturer and distributor of plant and animal nutrient products in China, entered into two new revolving credit facilities totaling $59 million.</description>
      <pubDate>9/2/2010 2:57:26 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910CHN13754.asp</guid>
    </item>
    <item>
      <title>Ono licenses Concordia''s cancer drug in Japan</title>
      <link>http://www.biospectrumasia.com/content/020910JPN13753.asp</link>
      <description>Concordia has granted Ono the exclusive rights to develop and commercialize salirasib in Japan</description>
      <pubDate>9/2/2010 2:42:06 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910JPN13753.asp</guid>
    </item>
    <item>
      <title>Another patent in Benitec''s Graham family allowed in US</title>
      <link>http://www.biospectrumasia.com/content/020910AUS13752.asp</link>
      <description>Benitec has updated on the progress of the patent family Control of Gene Expression, which are a part of the foundational Graham RNAi patent family.</description>
      <pubDate>9/2/2010 2:38:36 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910AUS13752.asp</guid>
    </item>
    <item>
      <title>Sun Pharma''s NJ unit receives warning from FDA</title>
      <link>http://www.biospectrumasia.com/content/020910IND13751.asp</link>
      <description>US Food and Drug Administration has warned the US unit of Indian drugmaker Sun Pharmaceutical for violations of current good manufacturing practice at a plant in New Jersey.</description>
      <pubDate>9/2/2010 12:42:00 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910IND13751.asp</guid>
    </item>
    <item>
      <title>GE healthcare, iBio, CMB execute business development and marketing agreement</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13750.asp</link>
      <description>GE Healthcare, iBio and Fraunhofer US Center for Molecular Biotechnology have entered into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines</description>
      <pubDate>9/2/2010 12:39:52 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13750.asp</guid>
    </item>
    <item>
      <title>ReproCELL to launch products on neuronalcells derived from human iPS cells</title>
      <link>http://www.biospectrumasia.com/content/020910JPN13749.asp</link>
      <description>ReproCELL, will launch a new line of products in the autumn of 2010, offering neuronal cells derived from human iPS cells and will provide dopaminergic neurons, motor neurons, and cerebral nerves</description>
      <pubDate>9/2/2010 12:36:44 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910JPN13749.asp</guid>
    </item>
    <item>
      <title>Philippines pharma market to grow at 4.94%</title>
      <link>http://www.biospectrumasia.com/content/020910PHL13748.asp</link>
      <description>Over the 2009-2014 forecast period, Business Monitor International expects the value of the Philippines drug market to increase by a CAGR of 4.94% in local currency terms, reaching $3.69bn (PHP151.3bn)</description>
      <pubDate>9/2/2010 11:42:18 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910PHL13748.asp</guid>
    </item>
    <item>
      <title>CARD develops innovative therapy for Multiple Sclerosis</title>
      <link>http://www.biospectrumasia.com/content/020910IND13747.asp</link>
      <description>Centre For Advanced Research and Development (CARD), of Scalene Cybernetics, a leader in innovative medical technologies is all set to make a pioneering contribution to the world of medicine for the treatment of Multiple Sclerosis</description>
      <pubDate>9/2/2010 11:37:46 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910IND13747.asp</guid>
    </item>
    <item>
      <title>9th Annual BIO Investor Forum in SF from Oct.5</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13746.asp</link>
      <description>BIO has announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum.</description>
      <pubDate>9/2/2010 9:47:00 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13746.asp</guid>
    </item>
    <item>
      <title>BARDA funds new treatment for illness from acute radiation</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13745.asp</link>
      <description>Biomedical Advanced Research and Development Authority has awarded a $153 million contract to Cellerant Therapeutics to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation.</description>
      <pubDate>9/2/2010 9:42:25 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13745.asp</guid>
    </item>
    <item>
      <title>Covidien sells Specialty Chemicals for $280 mn</title>
      <link>http://www.biospectrumasia.com/content/020910OTH13744.asp</link>
      <description>Covidien has announced that it has completed the previously announced sale of its Specialty Chemicals business to an affiliate of New Mountain Capital, L.L.C. for a cash purchase price of approximately $280 million.</description>
      <pubDate>9/2/2010 9:37:36 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/020910OTH13744.asp</guid>
    </item>
  </channel>
</rss>